These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11057342)

  • 21. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
    Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
    Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformation.
    Baba A; Tachi M; Maruyama Y; Kazama I
    Cell Physiol Biochem; 2015; 35(1):386-96. PubMed ID: 25591779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.
    Matsumoto Y; Funahashi J; Mori K; Hayashi K; Yano H
    Pharmacology; 2008; 81(3):266-74. PubMed ID: 18268402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats.
    Hayashi K; Kaise T; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Oct; 87(2):167-70. PubMed ID: 11700017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
    Cook EB; Stahl JL; Barney NP; Graziano FM
    Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
    Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
    J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen.
    Schoch C
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):75-81. PubMed ID: 12648306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice.
    Tamura T; Masaki S; Ohmori K; Karasawa A
    Pharmacology; 2005 Dec; 75(1):45-52. PubMed ID: 15942272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
    Hida WT; Nogueira DC; Schaefer A; Dantas PE; Dantas MC
    Arq Bras Oftalmol; 2006; 69(6):851-6. PubMed ID: 17273679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs.
    Miyake K; Horikoshi K; Ikeda Y; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Apr; 85(4):453-6. PubMed ID: 11388650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histamine H1-receptor antagonistic drug olopatadine suppresses TSLP in atopic dermatitis model mice.
    Higashi M; Ohsawa I; Oda F; Yamada Y; Kawana S; Iida K; Mitsuishi T
    Allergol Int; 2013 Mar; 62(1):137-8. PubMed ID: 23172358
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].
    Ohmori K; Ikemura T; Kobayashi H; Mukouyama A
    Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):51-8. PubMed ID: 11496828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils.
    Fukuishi N; Matsuhisa M; Shimono T; Murata N; Iwanaga M; Sagara H; Matsui N; Akagi M
    Jpn J Pharmacol; 2002 Apr; 88(4):463-6. PubMed ID: 12046991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the new antiallergic agent olopatadine on EEG spectral powers in conscious rats.
    Kamei C; Ichiki C; Izumo T; Ohishi H; Yoshida T; Tsujimoto S
    Arzneimittelforschung; 1996 Aug; 46(8):789-93. PubMed ID: 9125280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of triorganotin compounds on membrane permeability.
    Ortiz A; Teruel JA; Aranda FJ
    Biochim Biophys Acta; 2005 Dec; 1720(1-2):137-42. PubMed ID: 16472558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data.
    Kanamitsu K; Nozaki Y; Nagaya Y; Sugiyama Y; Kusuhara H
    Drug Metab Pharmacokinet; 2017 Apr; 32(2):135-144. PubMed ID: 28190755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.